Neutral endopeptidase inhibition in diabetic wound repair

Wound Repair and Regeneration

Volumn 10, Issue 5, 2002, Pages 295-301

  Spenny, Michelle L ^a   Muangman, Pornprom ^a   Sullivan, Stephen R ^a   Bunnett, Nigel W ^c   Ansel, John C ^d   Olerud, John E ^b   Gibran, Nicole S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GLUTARYLALANYLALANYLPHENYLALANINE 4 METHOXY 2 NAPHTHYLAMINE; MEMBRANE METALLOENDOPEPTIDASE; NAPHTHALENE DERIVATIVE; SUBSTANCE P; THIORPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIZATION; HISTOLOGY; INFLAMMATION; KINETICS; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN ULCER; TIME; ULCER HEALING; WOUND HEALING IMPAIRMENT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; NEPRILYSIN; OCCLUSIVE DRESSINGS; PROTEASE INHIBITORS; SKIN; THIORPHAN; WOUND HEALING;

EID: 0036427194     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.2002.10504.x     Document Type: Article

References (33)

1. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care 1999;22:1354-60.
2. McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecoraro RF. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995;18:216-9.
3. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157-62.
4. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. A case-control study. Ann Intern Med 1992;117:97-105.
5. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999;22:692-5.
6. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996;47:1042-8.
7. Levy DM, Terenghi G, Gu XH, Abraham RR, Springall DR, Polak JM. Immunohistochemical measurements of nerves and neuropeptides in diabetic skin: Relationship to tests of neurological function. Diabetologia 1992;35:889-97.
8. Lindberger M, Schroder HD, Schultzberg M, Kristensson K, Persson A, Ostman J, Link H. Nerve fibre studies in skin biopsies in peripheral neuropathies. I. Immunohistochemical analysis of neuropeptides in diabetes mellitus. J Neurol Sci 1989;93:289-96.
9. Eedy DJ. Neuropeptides in skin. Br J Dermatol 1993;128:597-605.
10. Gao XP, Rubinstein I. Neutral endopeptidase modulates substance P-induced vasodilation in vivo. J Appl Physiol 1995;78:562-8.
11. Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 1998;30:5-11.
12. Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D. Skin-nervous system interactions. J Invest Dermatol 1996;106:198-204.
13. Quinlan KL, Song IS, Bunnett NW, Letran E, Steinhoff M, Harten B, Olerud JE, Armstrong CA, Wright Caughman S, Ansel JC. Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. Am J Physiol 1998;275:C1580-90.
14. Quinlan KL, Song IS, Naik SM, Letran EL, Olerud JE, Bunnett NW, Armstrong CA, Caughman SW, AnselJC. VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. J Immunol 1999;162:1656-61.
15. Aronin N, Leeman SE, Clements RS Jr. Diminished flare response in neuropathic diabetic patients. Comparison of effects of substance P, histamine, and capsaicin. Diabetes 1987;36:1139-43.
16. Matsas R, Kenny J, Turner A. The metabolism of neuropeptides. Biochem J 1984;223:433-40.
17. Olerud JE, Usui ML, Seckin D, Chiu DS, Haycox CL, Song IS, Ansel JC, Bunnett NW. Neutral endopeptidase expression and distribution in human skin and wounds. J Invest Dermatol 1999;112:873-81.
18. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC. Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998;7:81-96.
19. Okamoto A, Lovett M, Payan DG, Bunnett NW. Interactions between neutral endopeptidase (EC 3.4.24.11) and the substance P (NK1) receptor expressed in mammalian cells. Biochem J 1994;299:683-93.
20. Coleman DL, Hummel KP. Studies with the mutation, diabetes, in the mouse. Diabetologia 1967;3:238-48.
21. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990;136:1235-46.
22. Underwood RA, Gibmn NS, Muffley LA, Usui ML, Olerud JE. Color subtractive-computer-assisted image analysis for quantification of cutaneous nerves in a diabetic mouse model. J Histochem Cytochem 2001;49:1285-91.
23. Terashima H, Okamoto A, Menozzi D, Goetzl EJ, Bunnett NW. Identification of neuropeptide-degrading enzymes in the pancreas. Peptides 1992;13:741-8.
24. Antezana M, Usui M, Gibran N, Larsen J, Ansel J, Bunnett N, Olerud J. Neutral endopeptidase activity is increased in skin and wounds of diabetic patients. J Invest Derm 1999;112:544. (Abstract)
25. Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 1990;40:264-78.
26. Borson DB, Gruenert DC. Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am J Physiol 1991;260:L83-9.
27. Takeshita N, Yoshino T, Mutoh S. Possible involvement of corticosterone in bone loss of genetically diabetic db/db mice. Horm Metab Res 2000;32:147-51.
28. Tanaka T, Danno K, Ikai K, Imamura S. Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol 1988;90:399-401.
29. Fernandes G, Handwerger BS, Yunis EJ, Brown DM. Immune response in the mutant diabetic C57BL/Ks-dt+ mouse. Discrepancies between in vitro and in vivo immunological assays. J Clin Invest 1978;61:243-50.
30. Caselgrandi E, Kletsas D, Ottaviani E. Neutral endopeptidase-24.11 (NEP) deactivates PDGF- and TGF-beta-induced cell shape changes in invertebrate immunocytes. Cell Biol Int 2000;24:8.5-90.
31. Turner AJ, Murphy LJ. Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 1996;51:91-102.
32. Oneda H, Inouye K. Interactions of human matrix metalloproteinase 7 (matrilysin) with the inhibitors thiorphan and R-94138. J Biochem (Tokyo) 2001;129:429-35.
33. Lu PC, Ye H, Maeda M, Azar DT. Immunolocalization and gene expression of matrilysin during corneal wound healing. Invest Ophthalmol Vis Sci 1999;40:20-7.